Kornimate/medical-research-clean huggingface dataset:
parkinson atypical rating of oculometric patterns evaluated routinely

Conditions: Parkinson Disease; Progressive Supranuclear Palsy(PSP); Multiple System Atrophy

Summary: this is an observational longitudinal study in 4 cohorts of patients with parkinsonian syndromes, who are visiting the movement disorders outpatient clinics. the aim of the study is to assess the difference of oculometric measures in different neurodegenerative brain conditions and their accuracy over time, and as compared to clinical diagnosis, in order to find a change over time, difference between subgroups and correlations with accepted clinical endpoints in subjects who meet the inclusion criteria and who provide a signed informed consent.

as a part of the study, about 40 subjects will undergo a neurological evaluation including motor and cognitive assessments and a neuralight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (tobii, ce-marked class b approved device). test duration will be approx. 20 minutes. the oculometric evaluation will occur for at least 50% of the cohort 3 times (at baseline, at 6-months and at 12-month follow-up), and all subjects will be recruited over a period of 9 months. all assessments will be performed during a clinic visit unless authorized to be conducted remotely.

Eligibility criteria:
inclusion criteria: * men and women, age between 40 and 80 years * \<5 years since disease diagnosis * normal or corrected vision * moca score ≥ 20 * ability to follow instructions * willing and able to sign an informed consent form specific * pd cohort: ages 50-80, hoehn \& yahr scale 1-3 * psp cohort: diagnosed according to actual diagnostic criteria from höglinger gu et al, 2017. * msa cohort: diagnosed according to actual diagnostic criteria from wenning et al, 2022. exclusion criteria: -
appraising clinical trial experiences of patients with insomnia

Conditions: Insomnia

Summary: medical research participation percentages haven't always been fully representative of a given demographic. the goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. the data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future insomnia patients during clinical study.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed. * participant has a diagnosis of insomnia. * willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study. exclusion criteria: * patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent. * known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results. * pregnant or lactating woman

Keywords: insomnia
preoperative relaxation and intensified patient surgery education in patients undergoing cholecystectomy

Conditions: Gall Stones

Summary: this study aims to test the effects of a preoperative relaxation intervention and an intensified surgery patient education on pre- and postoperative wellbeing and health in patients undergoing cholecystectomy.

see above

Eligibility criteria:
inclusion criteria: * 18 years old * referral for cholecystectomy * preoperative anxiety at least 4/10 points on a numeric rating scale * physical and mental capability to participant * written informed consent exclusion criteria: * emergency surgery * malignoma * severe comorbidity * severe psychological disorders * immunosuppression * coagulation disorders

Keywords: cholecystectomy
improving the diagnosis of pneumonia in emergency rooms

Conditions: Pneumonia

Summary: a point-of-care laboratory (poc) was set at north hospital, marseille, france for the diagnosis in less than two hours of pneumonia caused by known pathogens, close to the reception of emergency service. in this instance 30% of patients have no etiological diagnosis after the poc tests pneumonia. this lab has discovered over 200 new species of bacteria in humans, including vector bacteria and opened the field of large deoxyribo nucleic acid (dna ) viruses. also, the laboratory of emerging viruses discovered many ribo nucleic acid (rna) viruses transmitted by arthropods. based on this collection of new pathogens described in poc laboratory, this study proposes to expand the etiological diagnosis strategy of pneumonia after poc tests.


Eligibility criteria:
inclusion criteria: * patient admitted at hospital for pneumonia requiring, for the emergency physician, a microbiological examination with a "poc pneumonia kit." * patient who has freely signed the informed written consent * patient affiliated to a social security scheme exclusion criteria: * pregnant woman, parturient or nursing * adult major under guardianship * patient deprived of liberty under court order * patient refusing or unable to sign the informed consent form.
cle during exercise testing in asthma

Conditions: Larynx; Obstruction; Vocal Cord Dysfunction

Summary: the purpose is to assess visualize the level of laryngeal obstruction and vocal cord dysfunction and to obtain more information on causes for dyspnea in asthma and severe asthma and to assess safety of cle in patients with asthma and with severe asthma. patients are examined if symptomatic during exercise.

* questionnaires to assess breathlessness before the test. * cle on ergometer bicycle using any laryngoscopy setup * ergometry with spirometry tests with ecg, oxygen saturation, blood pressure, inspiratory and expiratory flow volume curves, bronchodilator after the exercise test * work load of 40w with 3 minutes intervals and increase by 40w in women. in men, work load of 50w with 3 minutes intervals and increase by 50w starting from 50w. in elderly and more severely disease work load of 30w with 3 minutes intervals and increase by 30w. * recording of dyspnoea, leg fatigue and chest discomfort * assessment of asthma by asthma control test, spirometry, exhaled no measurements. * severe asthma group: physician-diagnosed asthma, moderate-high dose inhaled glucorticoid steroids and a second controller drug, exacerbations and per oral glucocorticoid steroid courses at least 2 in the past 12 months and/or 50% of the past 12 months on per oral glucocorticoidsteroids

Eligibility criteria:
inclusion criteria: * physician diagnosed asthma * symptomatic during exercise exclusion criteria: * fev1 \<60% * respiratory infection in the last 14 days * asthma excacerbation in the last 14 days * unstable cardiovascular disease * bleeding disorder * anticoagulant treatment (other than asa)
prophylaxis against metoclopramide-induced akathisia

Conditions: Akathisia

Summary: abstract study objective: to compare the effects of midazolam and diphenhydramine for the prevention of metoclopramide induced akathisia. methods: this randomized, double-blind and controlled trial aimed to investigate co-administered midazolam versus diphenhydramine in the prophylaxis of metoclopramide induced akathisia. patients 18 through 65 years of age who presented to the ed with primary or secondary complaints of nausea and/or moderate to severe vascular type headache were eligible for this study. patients were randomized to one of the fallowing three groups: (1) metoclopramide 10 mg + midazolam 1.5 mg (2) metoclopramide 10 mg + diphenhydramine 20 mg (3) metoclopramide 10 mg + placebo. metoclopramide was administered as a 2 minutes bolus infusion. midazolam, diphenhydramine and normal saline solution administered as a 15 minutes slow infusion. whole procedure was observed, akathisia and sedation scores and vital changes were recorded.


Eligibility criteria:
inclusion criteria: * patients 18 through 65 years of age and 50-90 kg of weight who presented to the ed with primary or secondary complaints of nausea and/or moderate to severe vascular type headache were eligible for this study. exclusion criteria: * patients who had liver and renal insufficiency * electrolyte imbalance * acute respiratory symptoms * chronic obstructive pulmonary disease * blood pressure less than 90/60 mmhg * uncooperative individuals * pregnant or lactating * pre-existing motor disorder * restless legs syndrome-parkinson's disease * organic brain disorder, (dementia etc.), epilepsy * admitted to the ed due to acute psychiatric symptoms * deprived mental status * advanced hearing loss * malnutrition * acute asthma attack * serious physical illness, especially glaucoma, prostatic hypertrophy, or cardiac disease * had a contraindication to anticholinergic medications * within 3 days of study entry patients who had taken an antiemetic antihistaminic, antipsychotic, antispasmodic, alpha-blocker, or ca++2-channel blocker, or within 2 weeks of study entry patients who had taken an antidepressant, barbiturate, benzodiazepine, other sedative/hypnotic, opioid, lithium, or illicit sympathomimetic agent were excluded

Keywords: metoclopramide akathisia midazolam diphenhydramine metoclopramide induced akathisia
do müllerian anomalies affect embryo implantation?

Conditions: Uterine Diseases

Summary: müllerian anomalies (ma) are associated with infertility and affect approximately 6.3% of the infertile population. the estimation of the frequency of mas is not without controversy because it depends on the diagnostic method used and sometimes on the established diagnostic criteria. this pathology is associated with abortion during the second trimester in addition to other complications that include preterm labor, fetal malpositions and an increased rate of caesarean section, although some patients may remain asymptomatic. an association between ma and endometriosis has been described and in particular the case of the septum uterus, therefore it is difficult to establish whether the reproductive results of women with ma tdepend only on the uterine factor or also on the quality of the oocytes.

the main reproductive problems associated with these malformations include, abortion , recurrent abortion ectopic pregnancy and preterm delivery . the experience gained from oocyte donation shows that these women are pregnant less, even with the transfer of good quality embryos. the hypothesis of this poor uterine receptivity is in the poor endometrial vascularization that can decrease embryo implantation. the reason for infertility in women with am includes decreased muscle mass, decreased endometrial vascularization, decreased capacity of the endometrial cavity, less receptive areas (septum). the lower fertility observed in some women with müllerian malformations has been partially explained by its tubal factor and its association with endometriosis, with a higher prevalence in them, compared to patients without malformations. studies have confirmed an irregular differentiation and estrogenic maturation of the endometrium lining the uterine septum or its internal structure, which has less presence of connective tissue and more muscle mass. given the confusion generated if the unfavorable reproductive result is due to oocyte quality or endometrial receptivity, it is necessary to use a model that guarantees oocyte / embryo quality and this is offered by oocyte donation. the aim is to evaluate the implantation rate in women with ma who receive donated oocytes compared to women without ma.

Eligibility criteria:
inclusion criteria: * women included in the oocyte donation program at ivi vigo and valencia 2000-2019. * sperm count greater than 1,000,000 per ml. * transfer on day 5 of embryo development of at least one good quality embryo. exclusion criteria: * testicular biopsy. * any indication for preimplantation genetic diagnosis or screening. * uterine fibroid greater than 4 cm. * presence of ultrasound or diagnosis by hsg or laparoscopy of hydrosalpinx uni or bilateral. * recurrent abortion. * any abnormality of the uterine cavity other than ma: submucosal myoma, endometrial polyp, or uterine synechiae.
neurocognitive impairment and psychiatric comorbidities in hiv-1

Conditions: HIV Infections

Summary: to assess the prevalence and risk factors of neurocognitive impairment and psychiatric comorbidities in hiv infected patients who have undetectable viral load, have been on haart for at least 1 year and have no history of cns infection.

to understand how to prevent and treat hiv-associated neurocognitive impairment and psychiatric comorbidities in hiv-infected thai individuals who don't have current aids related illness or current and prior central nervous system (cns) infection, and have been well treated with haart with undetectable hiv rna.

Eligibility criteria:
inclusion criteria: * signed informed consent * evidence of hiv infection (confirmed positive elisa and documented history of measurable hiv rna) * age \> 18 years old * plasma hiv rna of \< 50 copies/ml within 3 months prior to screening * have been on only nnrti-based haart regimen for the entire duration and for at least1 year. exclusion criteria: * current aids defining illnesses * current or history of previous cns infection. * head injury with loss of consciousness greater than 1 hour * acute illness within 30 days prior to entry that, in the opinion of investigators, would prevent patients from completing the protocol required procedures. * known learning disability including dyslexia

Keywords: neuropsychiatric neurocognitive psychiatric hiv related dementia mcmd hiv-1 prevalence, risk factors of neurocognitive impairment and psychiatric comorbidities in hiv-1 infected patients with undetectable viral load in the haart era. treatment experienced
the impact pad study

Conditions: Peripheral Arterial Disease

Summary: defining the role of intraprocedural physiology measurements in peripheral endovascular treatment

endovascular treatment for peripheral arterial disease is commonly performed for claudication or critical limb threatening ischaemia (ischaemic rest pain, foot ulcer or gangrene). disease is generally identified using ankle brachial pressure index or toe brachial pressure index and then lesions delineated using doppler ultrasound or ct angiography. clinical severity is staged using absolute walking distance (metres) in claudicants or the society for vascular surgery wifi (wound, ischaemia, foot infection) score in critical limb threatening ischaemia patients. intra-procedural lesion assessment and quality control is currently performed anatomically using angiography alone, with a few centres using pullback pressures across a lesion to give supplementary trans-lesional gradients or intravascular ultrasound (ivus) to give pre and post intervention diameter and vessel area measurements. no direct or quantitative assessment of flow, or pressure normalisation across lesions is currently performed during interventions to improve blood flow to the leg.

Eligibility criteria:
inclusion criteria: * 18 years of age * peripheral arterial stenosis scheduled for endovascular treatment exclusion criteria: * \< 18 year of age * unable to give informed consent * estimated gfr ≤30 ml/min * dialysis dependent * unable to receive antiplatelets or periprocedural anticoagulation * pregnancy or breastfeeding * contraindication to adenosine (severe asthma or copd) * wifi ulcer score \<2 (no exposed bone) * wifi infection score \<2 (skin and subcutaneous tissues only) * wifi gangrene score \<3 (limited to digits) * covid-19 positive * nyha iv heart failure * contra-indication to adenosine including arrhythmia, asthma or allergy
integrated management enhances functional gains in children with cerebral palsy treated by bont-a

Conditions: Cerebral Palsy

Summary: evidence from literature support the use of botulinum toxin a (bont-a) for upper limb spasticity management in children with cerebral palsy (cp). constraint induced movement therapy (cimt) and bilateral intensive training (bit) are indicated as effective and complimentary treatments to improve motor function in these children. in a recent trial combined noninvasiv brain stimulation and cimt enhanced therapy induced functional gains. in this clinical trial the aim was to evaluate the effects of transcranial direct current stimulation (t-dcs) plus intensive hybrid training model of modified cimt and bit when integrated with bont-a treatment in children with unilateral cp.

although bont-a is effective in spasticity management there is inconclusive evidence to support its usage for improvement in upper limb activity and function. combination of bont-a and occupational therapy (ot) is found to be more effective then ot alone in reducing impairment, improving activity level and goal achievement. intensive hybrid training models of cimt and bit and noninvasive brain stimulation are promising treatments on motor learning in children with cp. the aim of this clinical trial is to show the additional gains that could be provided by an integrated treatment of transcranial direct current stimulation (t-dcs) plus intensive hybrid training model of modified cimt and bit to bont-a injections in children with unilateral cp.

Eligibility criteria:
inclusion criteria: * diagnosis of unilateral cerebral palsy * able to activate wrist and finger extensors * being scheduled for bont-a treatment for upper limb exclusion criteria: * significant loss of wrist and or fingers * history of orthopedic surgery to plegic upper limb

Keywords: cerebral palsy botulinum toxin a constraint induced movement therapy transcranial direct current stimulation
a randomized trial of gvs alone vs. propranolol

Conditions: Bleeding Gastric Varices; Liver Cirrhosis

Summary: design a randomized trial to compare the effect of endoscopic cyanoacrylate injection obliteration versus non-selective beta-blocker in the primary prevention of gastric variceal bleeding.

up to date, the treatment of gastric variceal bleeding (gvb) is still sub-optimal in contrast to the treatment of esophageal variceal bleeding (evb), which already had a big improvement of prognosis in recent two decades. gastric varices (gv) rarely rupture. however should it occur, the outcome would be worse than rupture of esophageal varies (ev). rupture of gv is characteristic of a higher rebleeding rate (90%), a requirement for a larger amount of blood transfusion and a higher mortality (40-50%). therefore, primary prevention of gv rupture is critically important. the management of gv has been focused on treatment of acute gvb. tissue adhesive (cyanoacrylate) may polymerize and occlude the vascular channels in seconds and obliterate for more than 70% cases of gv. the rebleeding rate after endoscopic cyanoacrylate injection(gvo) of acute gvb is around 30\~40% and expertise is required to reduce the embolic complications and instrumental injuries.gvo may arrest more than 90% active gvb. the 2005 baveno iv international consensus and 2007 aasld guidelines endorsed that endoscopic cyanoacrylate injection is the first line treatment for acute gvb. however, its efficacy on prevention of first gv bleeding is not known. non-selective beta-blocker (nsbb) is effective to prevent first and second bleeding from esophageal varices. the 2005 baveno iv international consensus and 2007 aasld guidelines also endorsed that nsbb is the first choice for the primary prevention of evb. however, its effect on gastric variceal hemorrhage has never been clarified. actually, gv usually has a large gastrorenal shunting and the portal pressure of gv is lower than that of ev. for ethical concerns, nsbb is usually be used for primary prevention of gvb, the preventive effect of nsbb had never been proved. study on the primary prevention of gvb is scanty. this is an important issue prompted by current portal hypertension experts. the investigators have a lot of experience in the treatment of gastric variceal bleeding and published fruitful results in high ranking journals. therefore, the investigators design a randomized trial to compare the effect of endoscopic cyanoacrylate injection obliteration versus non-selective beta-blocker in the primary prevention of gastric variceal bleeding.

Eligibility criteria:
inclusion criteria: 1. patients with live cirrhosis and/or hepatoma 2. aged 18 to 80, who had endoscopy-proven ev(-)gv(+)or ev\<gv exclusion criteria: 1. patients had previous endoscopic, surgical treatment or transjugular intrahepatic portosystemic shunt 2. had a terminal illness of any major organ system,such as heart failure, kindey failure,copd

Keywords: gastric variceal bleeding primaryprevention cyanoacrylate injection non-selective beta-blocker
study of the effect of the combined extract of lemon verbena and hibiscus on health indicators

Conditions: Diet, Mediterranean; Antioxidant Effect; Body Weight; Cardiovascular Diseases; Densitometry; Body Composition

Summary: plant polyphenols have demonstrated the ability to ameliorate metabolic alterations induced by overweight and obesity, both in cellular and animal models, where most therapeutic approaches have failed. these have demonstrated the ability to improve appetite sensation, leading to improved body weight control, in addition to reducing fat accumulation and improving plasma glycemic and lipid profiles, as well as inflammatory process and vascular dysfunction. the plant polyphenols on which the extract to be studied will be based will be hibiscus and lemon verbena. a randomized controlled trial will be carried out in overweight or obese subjects from the province of alicante. an electronic randomization will be carried out based on a two-branch design, therefore, there will be a control group (no intervention) and an experimental group (nutraceutical intake). participants will have to ingest the nutraceutical for 3 months, as well as attend the agreed visits. different satiety questionnaires, circulating parameters measured in capillaries (cholesterol, triglycerides and glucose), blood pressure and body composition measured by bone densitometry (dxa) will be collected. all variables will be measured at 4 different time points (baseline, 30 days, 60 days and 90 days). all these will be analyzed as a function of time; at the beginning and end of each intervention (intra-group analysis), as well as comparing the control group with the experimental group (inter-group analysis). a multidisciplinary team formed by physicians, nurses and nutritionists will be involved.


Eligibility criteria:
inclusion criteria: * elderly (\< 18 years) * overweight (body mass index 25-29.9 kg/m2) exclusion criteria: * pregnant or lactating subjects * who have participated in another study with similar characteristics in the last 3 months. * subjects with pathologies. * consumption of drugs and/or supplements * subjects with food intolerances/allergies. * subjects with muscle or joint injury. * subjects with impossibility to follow up the intervention. * refusal of informed consent